South Africa Sets 2028 Deadline for $9.3 Trillion OTC Derivatives Clearing Overhaul

R150 trillion in notional value, roughly $9.3 trillion, is the financial stake behind South Africa’s push to mandate central clearing of over-the-counter derivatives by 2028. The South African Reserve Bank confirmed the timeline in response to Bloomberg questions, signaling a structural shift in how the country’s largest financial markets will operate and who will bear the costs of that transition.

The regulatory framework carries a critical dependency. Market participants will only be required to comply once an appropriate central counterparty becomes licensed and operational. That sequencing creates a real constraint on the implementation schedule, even as rule-making advances.

The scale of the market explains why the mandate matters to investors and operators alike. Rand-linked OTC derivatives traded onshore and offshore exceed R150 trillion in notional value, according to the central bank. That breadth means compliance costs, operational investment in clearing infrastructure, and capital allocation decisions will fall across a wide range of institutions.

The Prudential Authority and Financial Sector Conduct Authority closed public comment on June 5 on a discussion document outlining proposed eligibility criteria for central clearing. The document reflects South Africa’s alignment with Group of Twenty commitments to reduce systemic risk in global derivatives markets. Rand-denominated interest-rate swaps and forward-rate agreements are proposed as the first category of OTC instruments subject to mandatory clearing, with additional derivatives phased in based on industry feedback and market-data analysis.

The implementation roadmap stretches across the next four years. Between April 2027 and March 2028, the PA and FSCA plan to issue a joint standard for consultation, accompanied by a draft joint determination specifying which products will be subject to mandatory central clearing. That standard will also establish the eligibility criteria OTC derivatives must meet to qualify.

By contrast, the global regulatory experience that shaped this approach took decades to consolidate. Regulators worldwide undertook comprehensive reviews of derivatives markets after counterparty failures demonstrated how cascading losses move across interconnected institutions. South Africa adopted its own phased roadmap in 2022, positioning 2028 as the culmination of a multi-year effort.

The economic case for centralizing and standardizing OTC derivative clearing rests on transparency and resilience. Clearing houses absorb counterparty risk, reducing the probability that a single institution’s failure destabilizes the broader financial system. For investors and capital allocators, that structural improvement is a precondition for sustained confidence in South African financial markets.

South Africa already has one licensed central counterparty for listed derivatives: JSE Clear, which operates on the Johannesburg Stock Exchange. That existing operator provides a foundation for the OTC clearing framework. The regulatory authorities have not yet confirmed, however, whether JSE Clear will serve as the central counterparty for OTC derivatives or whether additional licensing will be required.

That question carries real commercial weight. The timeline and operational readiness of whichever entity takes on the role will determine whether the 2028 target becomes binding. Delays in licensing or operationalization could push the effective compliance date beyond 2028, creating uncertainty for institutions already planning capital allocation and infrastructure investment around that deadline. Whether the licensing process moves fast enough to hold the schedule is the open question the market will be watching.